Clinical Trials Browser

Phase 1/2 × Sarcoma × Nivolumab × Clear all

NCT03465592 2026-02-05

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Phase 1/2 Recruiting

Sarcoma

NCT05407441 2025-10-03

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Phase 1/2 Recruiting

Chordoma, Sarcoma, Rhabdoid Tumor

NCT03138161 2025-02-24

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Phase 1/2 Recruiting

Sarcoma

NCT04165330 2025-02-24

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Phase 1/2 Active not recruiting

SarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Sarcoma, Small Cell Lung Carcinoma

NCT03277924 2024-08-13

ImmunoSarc

Phase 1/2 Completed

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT03435640 2023-03-08

REVEAL

Phase 1/2 Terminated

64 enrolled 22 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Recurrence, Sarcoma, Colorectal Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms